Table 2.
ANC and platelet count at day-28 after CAR T-cell infusion
| Variable | ANCs (×109/L) median (IQR) |
Platelets (×109/L) median (IQR) |
|---|---|---|
|
Disease cohort Total (n = 164) ALL (n = 59) CLL (n = 46) NHL (n = 59) |
1.52 (0.87, 2.46) 1.27 (0.62, 2.02) 1.61 (0.88, 2.82) 1.64 (1.06, 2.51) |
82 (46, 149) 77 (32, 146) 84 (43, 121) 88 (60, 179) |
|
Sex Female (n = 52) Male (n = 112) |
1.50 (0.92, 2.20) 1.55 (0.84, 2.54) |
72 (42, 130) 91 (51, 153) |
|
Race, n (%) White (n = 143) Nonwhite (n = 20) Unknown (n = 1) |
1.53 (0.88, 2.41) 1.35 (0.84, 2.61) 3.60 (3.60, 3.60) |
79 (44, 150) 112 (58, 154) 140 (140, 140) |
|
Number of prior therapies <Q1 (1-2) Q1-Q2 (3-4) Q2-Q3 (5-6) >Q3 (7-11) |
1.71 (0.95, 2.23) 1.31 (1.07, 2.50) 1.41 (0.78, 3.10) 1.60 (0.54, 2.44) |
126 (51, 171) 78 (43, 162) 66 (46, 116) 78 (42, 114) |
|
Prior HSCT Autologous (n = 22) Allogeneic (n = 34) Both (n = 3) None (n = 105) |
1.42 (1.02, 2.34) 1.36 (0.49, 1.74) 3.91 (3.56, 4.96) 1.58 (0.91, 2.53) |
70 (58, 149) 76 (28, 112) 88 (80, 152) 94 (50, 155) |
|
Pre-LD marrow abnormal B-cells (%) <Q1 (0-0.006) Q1-Q2 (0.006-7.99) Q2-Q3 (8.00-60.0) >Q3 (60.1-98.5) |
1.61 (1.02, 2.58) 1.72 (1.22, 2.55) 1.68 (1.24, 2.65) 0.80 (0.26, 1.93) |
91 (61, 178) 104 (56, 149) 78 (49, 147) 55 (27, 115) |
|
Pre-LD ANC (×109/L) <Q1 (0-1.35) Q1-Q2 (1.36-2.43) Q2-Q3 (2.44-4.34) >Q3 (4.35-23.17) |
1.00 (0.43, 1.90) 1.47 (1.14, 2.13) 1.74 (1.10, 2.84) 2.14 (1.17, 3.20) |
50 (24, 90) 101 (60, 147) 128 (62, 156) 86 (49, 201) |
|
Pre-LD ALC (×109/L) <Q1 (0.00-0.51) Q1-Q2 (0.52-0.89) Q2-Q3 (0.90-1.94) >Q3 (1.95-58.92) |
1.58 (0.79, 2.00) 1.36 (0.93, 2.45) 1.77 (1.24, 2.48) 1.35 (0.72, 2.31) |
61 (42, 113) 116 (45, 174) 83 (60, 147) 100 (41, 133) |
|
Pre-LD hemoglobin (g/dL) <Q1 (7.2-9.8) Q1-Q2 (9.9-10.8) Q2-Q3 (10.9-12.1) >Q3 (12.2-16.0) |
1.37 (0.58, 2.51) 1.69 (0.56, 2.22) 1.52 (1.03, 2.20) 1.70 (1.24, 2.71) |
64 (32, 107) 74 (37, 143) 83 (52, 142) 137 (70, 188) |
|
Pre-LD platelet (×109/L) <Q1 (7-66) Q1-Q2 (67-126) Q2-Q3 (127-197) >Q3 (198-448) |
0.66 (0.24, 1.41) 1.53 (1.10, 2.84) 1.68 (1.17, 2.23) 2.20 (1.24, 3.32) |
33 (20, 64) 79 (55, 115) 125 (62, 164) 174 (76, 215) |
|
Lymphodepletion High-intensity CyFlu (n = 77) Low-intensity CyFlu (n = 61) Non-CyFlu (n = 26) |
1.58 (1.07, 2.53) 1.53 (0.82, 2.39) 1.23 (0.88, 2.09) |
107 (55, 161) 62 (31, 113) 104 (60, 196) |
|
CAR T-cell dose DL1 (n = 46) DL2 (n = 108) DL3 (n = 10) |
1.21 (0.46, 2.10) 1.63 (1.02, 2.70) 1.53 (1.03, 2.15) |
86 (36, 155) 80 (54, 138) 144 (61, 217) |
|
CRS grade 0 (n = 50) 1 (n = 39) 2 (n = 53) 3-5 (n = 22) |
1.62 (1.01, 2.31) 1.97 (1.12, 3.11) 1.27 (0.81, 2.14) 1.44 (0.42, 2.22) |
89 (57, 172) 105 (58, 144) 84 (32, 147) 50 (26, 98) |
|
Neurotoxicity grade, n (%) 0-1 (n = 117) 2-3 (n = 44) 4-5 (n = 3) |
1.64 (0.99, 2.55) 1.28 (0.76, 2.04) 1.68 (1.17, 3.35) |
82 (50, 155) 85 (48, 130) 29 (28, 47) |
High-intensity CyFlu, cyclophosphamide (Cy) 60 mg/kg or > 1500 mg/m2 with fludarabine (Flu) 75-125 mg/m2; low-intensity CyFlu, Cy 30 mg/kg or ≤1500 mg/m2 with Flu 75-90 mg/m2; Non-CyFlu, any conditioning regimen other than as noted above including single agent Cy or Flu. CAR T-cell dose level (DL): DL1 = 2 × 105 cells/kg, DL2 = 2 × 106 cells/kg, DL3 = 2 × 107 cells/kg. CRS grade as defined by Lee criteria.24 Neurotoxicity grade as defined by CTCAE 4.0.3. ALC, absolute lymphocyte count; IQR, interquartile range; LD, lymphodepletion; Q1, 25% quantile (1st quartile); Q2, 50% quantile (median); Q3, 75% quantile (3rd quartile).